Revised Common Rule Reference Guide
The revised Common Rule introduces new exemptions, refined consent elements, and alters IRB oversight for multisite and minimal-risk research.
The revised Common Rule introduces new exemptions, refined consent elements, and alters IRB oversight for multisite and minimal-risk research.
Advarra’s institutional review board (IRB) strives to protect participant rights and welfare throughout the research process.
Discover how eSource platforms revolutionize clinical trials by simplifying data collection and ensuring accuracy, accessibility, and reliability.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Join this webinar to learn about FDA insights on DCTs and biologics. Dr. Eisenman discusses biosafety, risks, and key considerations for safe trials.
Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and strengthen oversight frameworks.
Conducting Research With CAR T Cells Regulatory and Practical Considerations Having proven successful in trials for blood cancers considered resistant
Onsemble Conference 2025 The Premier Technology Conference for the Clinical Research Site Community Join your Site and Institution peers to
This white paper examines four KPIs most impacting timelines and budgets and offers strategies for effective communication and risk mitigation.
Discover strategies for sponsors and CROs to navigate single IRB mandates, from institutional IRB roles to optimizing compliance and efficiency.